# Influenza, Human trials: 168 new since Nov 2024

Updated November 9, 2026.

168 clinical studies in Influenza, Human were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 61 have an industry sponsor and 103 are recruiting or about to. The newest, NCT07926217, was posted on November 9, 2026: High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving... (Sung-Han Kim).

## The full list

New Influenza, Human clinical trials: 168 rows for $8.40, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 11 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/influenza-human

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 168
- Industry sponsored: 61
- Recruiting or not yet: 103
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 168, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926217 | High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy | Sung-Han Kim | Phase 2 | Recruiting | Hematologic Malignancy, Influenza | 60 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926217) |
| November 3, 2026 | NCT07914673 | Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in Humans | Washington University School of Medicine | Phase 4 | Recruiting | Healthy Adult Participants, Age 65 and Older, Age 18 to 40, Immunology | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914673) |
| November 2, 2026 | NCT07910266 | Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza Vaccination | University of Missouri-Columbia | Phase 4 | Recruiting | Immunology | 220 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910266) |
| October 28, 2026 | NCT07901673 | Information-Based Interventions for Influenza Vaccination Among Older Adults With Diabetes in Yangzhou, China | Southeast University, China | Not applicable | Completed | Diabetes Mellitus, Type 2, Influenza | 759 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901673) |
| October 27, 2026 | NCT07896850 | Conversational AI for Adult Flu Vaccination Decisions | Calypta Systems, Inc. | Not applicable | Active not recruiting | Influenza, Human, Vaccine Hesitancy | 220 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896850) |
| October 26, 2026 | NCT07893847 | Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza | Capital Medical University | Phase 2/3 | Not yet recruiting | Influenza, Human | 570 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893847) |
| October 23, 2026 | NCT07892872 | Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections | Capital Medical University | Not applicable | Not yet recruiting | Respiratory Viral Infections, Influenza, SARS CoV 2 Infection | 618 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892872) |
| October 22, 2026 | NCT07890454 | Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult... | Sanofi | Phase 3 | Not yet recruiting | Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization | 6,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890454) |
| October 21, 2026 | NCT07885540 | Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for... | The First Affiliated Hospital of Guangzhou Medical University | Phase 4 | Not yet recruiting | Pneumococcal Polysaccharide Vaccine, Influenza Vaccines, Preoperative, Lung Resection Surgery, Thoracic Surgery | 1,278 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885540) |
| October 20, 2026 | NCT07884175 | A Study of Updated mRNA Seasonal Influenza Vaccines | ModernaTX, Inc. | Phase 4 | Not yet recruiting | Seasonal Influenza | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884175) |
| October 20, 2026 | NCT07883928 | Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older | GC Biopharma Corp | Phase 2/3 | Not yet recruiting | Influenza A, Influenza B, Influenza Vaccination | 1,806 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883928) |
| October 20, 2026 | NCT07883421 | Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in Singapore | Tan Tock Seng Hospital | Phase 4 | Not yet recruiting | Influenza | 150 | Singapore | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883421) |
| October 20, 2026 | NCT07882186 | Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the... | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Vaccination Coverage Among Pregnant Women | 1,605 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882186) |
| October 19, 2026 | NCT07880158 | Sequential Digital Intervention to Increase Influenza Vaccination in Patients With Heart Failure | Heart Health Research Center | Not applicable | Not yet recruiting | Heart Failure, Influenza Vaccination | 588 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880158) |
| October 14, 2026 | NCT07873671 | A Trial of RLX-2508-102 in Healthy Volunteers | Atridia Pty Ltd. | Early phase 1 | Not yet recruiting | Influenza | 101 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873671) |
| October 14, 2026 | NCT07873255 | Artificial Intelligence-assisted Primary Care for Influenza Vaccination Among Chronic Patients in China (AIPC-Flu) | Fudan University | Not applicable | Not yet recruiting | Influenza Vaccination | 1,300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873255) |
| October 13, 2026 | NCT07871448 | Flu COVID Vaccine Views | George Washington University | Observational | Not yet recruiting | Influenza, COVID-19, Vaccination Willingness | 550 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871448) |
| October 13, 2026 | NCT07870330 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children | ModernaTX, Inc. | Phase 1 | Recruiting | Seasonal Influenza | 96 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870330) |
| October 8, 2026 | NCT07864597 | Family Physician Nudges for Influenza Vaccination Among Older Adults | Fudan University | Not applicable | Not yet recruiting | Influenza Vaccination | 3,060 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864597) |
| October 6, 2026 | NCT07861854 | Mucosal and Systemic Immunity Correlates of Protection Against Influenza in Young Children, Aged 2-5 Years (MUSIC-Flu) | National Institute for Communicable Diseases, South Africa | Observational | Recruiting | Influenza -Like Illness, Influenza (Healthy Volunteers) | 150 | South Africa | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861854) |
| October 2, 2026 | NCT07854392 | A Study to Evaluate the Immune Responses of Subunit Influenza Vaccine in Healthy Adults | Ab&B Bio-tech Co., Ltd.JS | Phase 4 | Active not recruiting | Influenza | 138 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854392) |
| October 1, 2026 | NCT07851246 | A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | GlaxoSmithKline | Phase 3 | Recruiting | Influenza, Human | 3,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851246) |
| September 29, 2026 | NCT07846423 | Abbott ID NOW Point-of-Care Testing | China Medical University Hospital | Not applicable | Recruiting | Influenza, Influenza-like Illness | 1,080 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846423) |
| September 24, 2026 | NCT07838298 | Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults | Korea University Guro Hospital | Phase 4 | Recruiting | Influenza Vaccination, Older Adults (65 Years and Older), Immunosenescence, Immunogenicity, Repeated Vaccination | 180 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838298) |
| September 21, 2026 | NCT07832201 | A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG) | Sinovac Biotech Co., Ltd | Phase 4 | Not yet recruiting | Influenza | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832201) |
| September 18, 2026 | NCT07827599 | A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in... | Hoffmann-La Roche | Phase 3 | Recruiting | Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis | 325 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827599) |
| September 11, 2026 | NCT07816471 | RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed Adults | Hospital Italiano de Buenos Aires | Observational | Active not recruiting | Respiratory Syncytial Virus Infections, Immunocompromised Host, Influenza, COVID - 19 | 350 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816471) |
| September 11, 2026 | NCT07814495 | A Human Influenza Transmission Study Using Naturally Infected Community Donors | Emory University | Not applicable | Not yet recruiting | Influenza | 150 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814495) |
| September 4, 2026 | NCT07805837 | Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older Adults | Korea University Guro Hospital | Phase 4 | Completed | Influenza, Influenza Vaccines, Microbiome, Immune Response | 121 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805837) |
| September 4, 2026 | NCT07805707 | A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age | GlaxoSmithKline | Phase 3 | Recruiting | Influenza, Human | 54,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805707) |
| September 2, 2026 | NCT07798882 | Rule-Based High-Risk Flu | Geisinger Clinic | Not applicable | Completed | Influenza, Vaccination, Risk Reduction, Health Behavior, Health Promotion | 51,218 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798882) |
| September 1, 2026 | NCT07798193 | A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza. | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Influenza | 213 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798193) |
| August 27, 2026 | NCT07790523 | Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax \[mRNA-1083\]) in Adults ≥ 65 Years | Tor Biering-Sørensen | Phase 4 | Not yet recruiting | COVID-19, Influenza | 410,000 | Denmark, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790523) |
| August 26, 2026 | NCT07786662 | Early Corticosteroids in Severe Influenza Pneumonia | Centre Hospitalier Régional Metz-Thionville | Phase 3 | Not yet recruiting | Severe Influenza, Intensive Care (ICU), Reanimation, Infectious Diseases, Hygiene | 544 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786662) |
| August 26, 2026 | NCT07786467 | Optimizing Lymphatic Pumping for Influenza Vaccine Responses in Vulnerable Populations | Lake Erie College of Osteopathic Medicine | Not applicable | Recruiting | No Disease or Condition is Being Directly Studied, The Focus of the Study in Healthy Volunteers | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786467) |
| August 21, 2026 | NCT07779408 | Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in... | Sanofi | Phase 1/2 | Recruiting | Healthy Volunteers, Influenza | 640 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779408) |
| August 17, 2026 | NCT07767019 | Climate Change Trends and Their Impact on the Seasonal Upper Respiratory Tract Disease Burden | Barzilai Medical Center | Observational | Not yet recruiting | Upper Resp Tract Infection | 5,000 | Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767019) |
| July 31, 2026 | NCT07739719 | SAFE (Self-Administration of Flumist to ImprovE Uptake: A Household-Based Cluster Randomized Trial) | McMaster University | Phase 4 | Not yet recruiting | Influenza (Healthy Volunteers) | 966 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739719) |
| July 31, 2026 | NCT07739446 | Effect of Surgical Masks in Preventing Acute Respiratory Infections | Chiba University | Not applicable | Enrolling by invitation | Acute Respiratory Infections (ARIs), Influenza, COVID - 19 | 2,400 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739446) |
| July 30, 2026 | NCT07737106 | Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose) | Sinovac Biotech Co., Ltd | Phase 1 | Completed | Influenza | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737106) |
| July 24, 2026 | NCT07726862 | How Healthy Adults Respond to the Nasal Flu Vaccine | University of Alabama at Birmingham | Phase 4 | Not yet recruiting | Mucosal Immune Response to Influenza Vaccination | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726862) |
| July 23, 2026 | NCT07721649 | Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP) | Stephan Baldus | Not applicable | Recruiting | Acute Coronary Syndrome, Heart Failure, Influenza, Human, Cardiovascular Diseases, Vaccination Refusal | 482 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721649) |
| July 17, 2026 | NCT07710586 | Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in China | Ab&B Bio-tech Co., Ltd.JS | Phase 4 | Completed | Influenza Vaccine | 3,105 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710586) |
| July 14, 2026 | NCT07703514 | Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | Influenza | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703514) |
| July 1, 2026 | NCT07678619 | Smart Analysis and Decision-Making for Emerging Infectious Diseases | Peking University | Not applicable | Enrolling by invitation | Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox), Dengue Fever, Chikungunya Fever, Avian Influenza | 108 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678619) |
| June 29, 2026 | NCT07673250 | Personalized Ventilator Settings for Patients on ECMO | University of California, San Diego | Not applicable | Enrolling by invitation | Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation, Respiratory Failure Patients Treated... | 62 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673250) |
| June 16, 2026 | NCT07651761 | Patient-Centered Practical Vaccine Talk For Busy Clinicians | University of Massachusetts, Worcester | Not applicable | Enrolling by invitation | Influenza, COVID-19 | 24,500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651761) |
| June 12, 2026 | NCT07645534 | Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90... | Valenta Pharm JSC | Phase 1 | Recruiting | Influenza, Acute Respiratory Viral Infections | 36 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645534) |
| June 12, 2026 | NCT07644546 | Immunogenicity of MF59-adjuvanted Versus High-dose Influenza Vaccine in People With HIV: a Randomized Clinical Trial | National Taiwan University Hospital | Not applicable | Not yet recruiting | HIV | 350 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644546) |
| June 11, 2026 | NCT07643688 | Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections | Fabiana Sherine Ganem dos Santos | Observational | Not yet recruiting | SARS CoV 2 Infection, RSV Infections, Influenza Infection | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643688) |
| June 11, 2026 | NCT07640841 | Health Economic Evaluation of Influenza and Pneumococcal Vaccination in COPD Patients | Jiangsu Province Centers for Disease Control and Prevention | Phase 4 | Not yet recruiting | Influenza and Pneumonia | 7,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640841) |
| June 8, 2026 | NCT07633366 | BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics | Medical University of Vienna | Observational | Recruiting | ARDS (Acute Respiratory Distress Syndrome) | 130 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633366) |
| June 8, 2026 | NCT07633288 | A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With... | SynAct Pharma Aps | Phase 2 | Recruiting | Respiratory Viral Infection | 96 | Bosnia and Herzegovina, Montenegro, New Zealand, Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633288) |
| June 4, 2026 | NCT07626437 | Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common... | Brainfarma Industria Química e Farmacêutica S/A | Phase 3 | Recruiting | Common Cold/Flu, Nasal Congestion, Nasal Obstruction | 620 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07626437) |
| June 1, 2026 | NCT07617376 | Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions | Wroclaw Medical University | Phase 4 | Recruiting | Myocardial Infarction, Decompensated Chronic Heart Failure, Acute Heart Failure (AHF), Pulmonary Embolism Acute... | 400 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617376) |
| May 28, 2026 | NCT07610967 | Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections | David Moss | Not applicable | Recruiting | COVID-19 Respiratory Infection, Influenza | 130 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610967) |
| May 22, 2026 | NCT07604103 | Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute... | University of Brawijaya | Phase 3 | Recruiting | Acute Coronary Syndromes (ACS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease) | 60 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604103) |
| May 22, 2026 | NCT07601126 | Respiratory Pathogen Distribution During and After the COVID-19 Pandemic | Hisar Intercontinental Hospital | Observational | Completed | Viral Respiratory Infection (e.g., Influenza), Bacterial Respiratory Infections | 537 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601126) |
| May 20, 2026 | NCT07599449 | Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France | Institut National de la Santé Et de la Recherche Médicale, France | Observational | Recruiting | Respiratory Tract Infections (RTI), Influenza -Like Illness, Influenza, COVID - 19, RSV Infections, Rhinovirus... | 25,000 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599449) |
| May 14, 2026 | NCT07587801 | Vaccination Response Modulation With a Targeted Rapamycin Protocol Study | Central Adelaide Local Health Network Incorporated | Phase 2 | Not yet recruiting | Vaccine Immune Response, Haemodialysis Patients, Older Adults | 60 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07587801) |
| April 22, 2026 | NCT07545564 | A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine | Changchun BCHT Biotechnology Co. | Phase 4 | Enrolling by invitation | Influenza | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545564) |
| April 13, 2026 | NCT07526506 | Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers | Traws Pharma, Inc. | Phase 1 | Recruiting | Healthy Volunteer | 32 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526506) |
| April 8, 2026 | NCT07516977 | Noseguard for Prevention of Respiratory Infections in Real-World Use | Daewoong Pharmaceutical Co. LTD. | Not applicable | Not yet recruiting | Respiratory Infection Virus, COVID-19, Influenza | 2,000 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516977) |
| April 8, 2026 | NCT07516418 | Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | Sanofi | Phase 1 | Recruiting | Respiratory Syncytial Virus (RSV), Influenza A(H5N1) | 570 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516418) |
| April 2, 2026 | NCT07508189 | Communication Intervention to Improve Influenza Vaccination Rates Among Elderly in Can Tho | Can Tho University of Medicine and Pharmacy | Not applicable | Completed | Influenza, Vaccination Coverage, Health Communication | 1,237 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508189) |
| March 31, 2026 | NCT07503405 | Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | Traws Pharma, Inc. | Phase 2 | Not yet recruiting | Influenza | 165 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503405) |
| March 27, 2026 | NCT07496736 | Post-exposure Influenza Prophylaxis in a Hospital Setting | University Medical Centre Ljubljana | Phase 3 | Active not recruiting | Influenza | 200 | Slovenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07496736) |
| March 27, 2026 | NCT07496450 | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | ModernaTX, Inc. | Phase 3 | Active not recruiting | Influenza | 4,050 | United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07496450) |
| March 20, 2026 | NCT07485855 | Influenza Vaccination Strategy for Patients With Hematologic Malignancy | Asan Medical Center | Phase 3 | Recruiting | Hematologic Neoplasms, Influenza, Immunogenicity | 120 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485855) |
| March 11, 2026 | NCT07464314 | A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults | GlaxoSmithKline | Phase 1 | Recruiting | Influenza, Human+COVID-19 | 225 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464314) |
| February 25, 2026 | NCT07431853 | A Study to Learn About mRNA Vaccines Against Influenza in Adults | Pfizer | Phase 2 | Recruiting | Healthy Adults | 770 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431853) |
| February 25, 2026 | NCT07431840 | Immune Defense Protein Impact On Respiratory Immune Outcomes | Quantec Ltd | Not applicable | Recruiting | Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection | 300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431840) |
| February 19, 2026 | NCT07421050 | Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older | Ab&B Bio-tech Co., Ltd.JS | Phase 1 | Active not recruiting | Influenza, Influenza Vaccine | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421050) |
| February 19, 2026 | NCT07421037 | Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older | Ab&B Bio-tech Co., Ltd.JS | Phase 1 | Active not recruiting | Influenza, Influenza Vaccine | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421037) |
| February 19, 2026 | NCT07420985 | Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects... | Valenta Pharm JSC | Phase 2 | Recruiting | Influenza, Acute Respiratory Viral Infection | 300 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420985) |
| February 18, 2026 | NCT07416266 | Lower Respiratory Tract Infections Managed in Primary Care in France | Hôpital Raymond Poincaré | Observational | Completed | Lower Respiratory Tract Infections, Community Acquired Pneumonia (CAP), Acute Bronchitis, Acute Exacerbation Chronic... | 230,066 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416266) |
| February 6, 2026 | NCT07393685 | Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD | Tianjin Medical University | Observational | Not yet recruiting | Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases | 300 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393685) |
| January 28, 2026 | NCT07372950 | Kaiser Colorado Flu Nudge | Kaiser Permanente | Not applicable | Active not recruiting | Influenza, Vaccination | 100,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07372950) |
| January 28, 2026 | NCT07371650 | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate... | Traws Pharma, Inc. | Phase 2 | Active not recruiting | Influenza | 105 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371650) |
| January 22, 2026 | NCT07359287 | Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care | University Hospital, Caen | Not applicable | Recruiting | Angina, Acute Bronchiolitis, Acute Bronchitis, COPD Exacerbation (AECOPD), Laryngitis, Acute Otitis Media (AOM), Serous... | 4,500 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359287) |
| January 22, 2026 | NCT07357467 | Effect of Oral Supplement on Influenza Vaccine Long-term Response | Tsinghua University | Observational | Not yet recruiting | Influenza, Immunosenescence | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07357467) |
| January 20, 2026 | NCT07351500 | Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults | Qingyuan Zhan | Phase 3 | Not yet recruiting | Influenza | 496 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351500) |
| January 16, 2026 | NCT07349017 | A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant) | Changchun BCHT Biotechnology Co. | Phase 1 | Not yet recruiting | Influenza | 160 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349017) |
| January 15, 2026 | NCT07342556 | Evaluating Modes of Influenza Transmission 2b Baseline SAR | University of Maryland, College Park | Not applicable | Not yet recruiting | Influenza (Healthy Volunteers) | 80 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07342556) |
| January 14, 2026 | NCT07340047 | H1ssF Flu Vaccine Clinical Trial | University of Minnesota | Phase 1 | Withdrawn | Influenza | 0 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07340047) |
| January 12, 2026 | NCT07332689 | Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older | Ab&B Bio-tech Co., Ltd.JS | Observational | Completed | Influenza Vaccine | 42,881 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332689) |
| January 8, 2026 | NCT07327398 | Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above | Shanghai Institute Of Biological Products | Phase 2 | Not yet recruiting | Influenza | 1,200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07327398) |
| January 2, 2026 | NCT07314905 | Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | Unity Health Toronto | Phase 3 | Recruiting | Influenza A, Influenza B, SAR-CoV-2, Acute Respiratory Infections (ARIs) | 264 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314905) |
| January 2, 2026 | NCT07314593 | Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults. | Landspitali University Hospital | Not applicable | Recruiting | Respiratory Infections | 400 | Iceland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314593) |
| December 30, 2025 | NCT07310472 | Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility | Turku University Hospital | Not applicable | Recruiting | Influenza Vaccination | 6,000 | Finland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07310472) |
| December 26, 2025 | NCT07305207 | Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness | Dalhousie University | Phase 1 | Recruiting | Influenza (Healthy Volunteers) | 32 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07305207) |
| December 24, 2025 | NCT07302256 | A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above | Shanghai Institute Of Biological Products | Phase 1 | Recruiting | Influenza | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07302256) |
| December 23, 2025 | NCT07300085 | A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 | Recruiting | Healthy Participants | 710 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300085) |
| December 18, 2025 | NCT07291635 | Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine | Aramis Biotechnologies Inc. | Phase 1/2 | Active not recruiting | Influenza | 728 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07291635) |
| December 17, 2025 | NCT07287137 | Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study | Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 4 | Recruiting | COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection... | 54 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287137) |
| December 15, 2025 | NCT07282795 | Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe | Sanofi | Observational | Recruiting | Influenza Immunization, Healthy Volunteers | 670 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282795) |
| November 28, 2025 | NCT07254052 | Effectiveness of Ammonium Chloride in Reducing Viral Load | National and Kapodistrian University of Athens | Observational | Completed | RNA Virus Infections, Viral Infection COVID-19, Influenza A and B | 32 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254052) |
| November 25, 2025 | NCT07248319 | Production and Evaluation of an Evidence-based Health Awareness Video on Precautionary Measures Against Respiratory Infectious Diseases... | Lebanese American University | Not applicable | Not yet recruiting | Produce and Evaluate an Evidence-based Health Awareness Video | 160 | Lebanon | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07248319) |
| November 21, 2025 | NCT07240922 | The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study | The University of Hong Kong | Phase 4 | Active not recruiting | Influenza | 600 | Hong Kong | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07240922) |
| November 21, 2025 | NCT07240558 | Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) | University Health Network, Toronto | Phase 3 | Active not recruiting | Influenza (Pandemic), Avian Influenza, Vaccination | 120 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07240558) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Sanofi | 9 | October 22, 2026 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 7 | July 14, 2026 |
| ModernaTX, Inc. | 5 | October 20, 2026 |
| Ab&B Bio-tech Co., Ltd.JS | 5 | October 2, 2026 |
| GlaxoSmithKline | 5 | October 1, 2026 |
| Capital Medical University | 4 | October 26, 2026 |
| Washington University School of Medicine | 3 | November 3, 2026 |
| Sinovac Biotech Co., Ltd | 3 | September 21, 2026 |
| Emory University | 3 | September 11, 2026 |
| Valenta Pharm JSC | 3 | June 12, 2026 |
| Traws Pharma, Inc. | 3 | April 13, 2026 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 3 | December 23, 2025 |
| Sanofi Pasteur, a Sanofi Company | 3 | January 30, 2025 |
| Fudan University | 2 | October 14, 2026 |
| Korea University Guro Hospital | 2 | September 24, 2026 |
| Hoffmann-La Roche | 2 | September 18, 2026 |
| National Taiwan University Hospital | 2 | June 12, 2026 |
| Jiangsu Province Centers for Disease Control and Prevention | 2 | June 11, 2026 |
| Wroclaw Medical University | 2 | June 1, 2026 |
| Changchun BCHT Biotechnology Co. | 2 | April 22, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 39 | October 28, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 29 | October 20, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 25 | November 3, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 23 | October 13, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 22 | October 22, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 16 | November 9, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 10 | August 21, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 2 | October 26, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 2 | October 14, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 55 | November 3, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 26 | October 28, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 9 | November 9, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 9 | October 14, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 6 | October 20, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 6 | July 31, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 5 | March 31, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 4 | September 29, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 3 | July 31, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 3 | July 23, 2026 |
| [Russia](https://specstream.ai/data/clinical-trials/country/russia) | 3 | June 12, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 3 | October 3, 2025 |
| [South Africa](https://specstream.ai/data/clinical-trials/country/south-africa) | 2 | October 6, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 2 | August 27, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 2 | August 17, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 2 | June 1, 2026 |
| [Hong Kong](https://specstream.ai/data/clinical-trials/country/hong-kong) | 2 | November 21, 2025 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 2 | December 20, 2024 |
| [Singapore](https://specstream.ai/data/clinical-trials/country/singapore) | 1 | October 20, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 1 | August 27, 2026 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 1 | June 8, 2026 |
| [Bosnia and Herzegovina](https://specstream.ai/data/clinical-trials/country/bosnia-and-herzegovina) | 1 | June 8, 2026 |
| Montenegro | 1 | June 8, 2026 |
| [New Zealand](https://specstream.ai/data/clinical-trials/country/new-zealand) | 1 | June 8, 2026 |
| [Serbia](https://specstream.ai/data/clinical-trials/country/serbia) | 1 | June 8, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).